Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abu Dhabi DoH, AbbVie, M42 Partner on Personalized Medicine | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Abu Dhabi DoH, AbbVie, M42 Partner on Personalized Medicine

Aims to advance precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer in UAE.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding with AbbVie and M42 for collaborative efforts in tailoring personalized medicine and genomics in Abu Dhabi. M42 is a tech-enabled, integrated healthcare company comprised of G42 Healthcare and Mubadala Health.
 
The three parties aim to advance precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer. DoH aims to drive research that will contribute to policy changes and guideline implementation which will enable broader patient access to innovative approaches in healthcare.

As part of its preventive healthcare efforts, Abu Dhabi launched the region’s first Personalized Precision Medicine Program for oncology in 2022. The program integrates predictive, personalized and precision medicine using genomics to transform diagnostics, drug therapy and prevention and tailor it to the needs specific to individuals.
 
Hassan Sabbah, General Manager AbbVie Gulf & Levant said: “This partnership aims to advance precision medicine in the diagnosis and treatment to help enable broader patient access in UAE to innovative therapies. Our efforts are progressing to launch several initiatives that support research and clinical trials and develop innovative solutions to deal effectively with local and regional health needs, challenges, and burdens.”
 
Francesco Redivo, Senior Director at G42 Healthcare, a M42 company said: “I am proud to witness how our vision of realizing personalized healthcare is progressing forward. Our collaboration will be built on joint efforts to advance precision medicine by harnessing real world evidence capabilities, shaping innovative solutions around access to care and translating scientific advancements into tangible patient benefits by maximizing the potential of Emirati Genome Program.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics